Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
NEW YORK (Reuters Breakingviews) - Apple may anoint the winner of Broadcom's $105 billion bid for Qualcomm. A dispute over iPhone royalties left the U.S. chipmaker vulnerable to an opportunistic offer from its acquisitive rival. Settling could preserve Qualcomm’s independence – but it all depends on whether Apple thinks a bigger Broadcom would be slavishly devoted to the handset maker, or just surlier.
NEW YORK (Reuters Breakingviews) - Aetna's third-quarter results lay out its insurance value for CVS Health. Revenue at the $56 billion health-coverage firm fell 5 percent in the three months to the end of September, partly from dumping some Obamacare policies. But profit jumped 48 percent as the company kept costs under control. That offers alluring protection for CVS, whose pharmacy and drug-benefit business is threatened by rising competition and transparency.
NEW YORK (Reuters Breakingviews) - A bid for Aetna is a defensive prescription for CVS Health. The drugstore and pharmacy-benefit company should be able to generate some cost savings if its $66 billion offer for the health insurer prevails. Even more important, it could help the firm resist Amazon’s entry into drug distribution, and the unpleasant side effects of transparency and low margins that may follow.
NEW YORK (Reuters Breakingviews) - PayPal's future rests on striking a quadruple whammy. The $80 billion payments firm, which announced estimates-beating third-quarter earnings on Thursday, is worth as much as American Express – more, if an after-hours bump in its stock holds up. At 31 times the next 12 months’ estimated earnings, it trades at a higher multiple than Visa or MasterCard. Justifying such a rapid rise requires Chief Executive Dan Schulman to execute well on four crucial strategies.
NEW YORK (Reuters Breakingviews) - Two rights at Uber are in danger of making a wrong. Travis Kalanick's newly appointed directors add useful expertise to a flawed board. And the effort by incumbents to limit the ousted founder's power as part of a deal to raise capital from SoftBank also makes sense. Both stand to lose, though, if they dig in too firmly against each other.
NEW YORK (Reuters Breakingviews) - Alphabet has cleared the deck for a huge antitrust fight. The holding company of Google is separating its European shopping unit and allowing rivals to bid for ads. That frees up Google to battle the EU over claims it uses its Android operating system to dominate online search.
NEW YORK (Reuters Breakingviews) - Equifax can't even oust its hapless chairman and chief executive effectively. Rick Smith is "retiring," as the corporate euphemism goes, after failing to prevent a massive cyber attack and fumbling the response - and with little financial penalty to boot. An interim management plan makes clear the board hadn't planned succession adequately either. Equifax needs regime change at every level.
［ニューヨーク ５日 ロイター BREAKINGVIEWS］ - デンマークの玩具メーカー、レゴ・グループは、バーチャルな壁に突き当たった。１０年に及ぶレゴ製品ブームに陰りが見えるなか、同社は１４００人の人員削減を決めた。
NEW YORK (Reuters Breakingviews) - United Technologies’ avionics bid looks airworthy. The conglomerate’s potential acquisition of Rockwell Collins should deliver enough cost savings to justify paying a reported price tag of nearly $23 billion. Greater size also promises increased negotiating heft with Boeing and Airbus. Investors have good reason to clear this deal for takeoff.
［ニューヨーク ２４日 ロイター BREAKINGVIEWS］ - 製薬会社は長年にわたり鎮痛剤を販売しており、そうした薬品を扱うディーラーや密輸業者が暗躍する闇市場は、活況を呈している。だがその一方で、鎮痛剤中毒を巡る米国の経済活動は、社会の中心にまで広く浸透している。